1 / 24

History of the Montreal Protocol and 21 CFR 2.125

History of the Montreal Protocol and 21 CFR 2.125. Robert J. Meyer, MD Director, ODE II / CDER. General Background. The earth’s stratospheric ozone layer provides reductions in ultraviolet radiation (UV-B) reaching the surface

tia
Télécharger la présentation

History of the Montreal Protocol and 21 CFR 2.125

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. History of the Montreal Protocol and 21 CFR 2.125 Robert J. Meyer, MD Director, ODE II / CDER

  2. General Background • The earth’s stratospheric ozone layer provides reductions in ultraviolet radiation (UV-B) reaching the surface • Increases in UV-B can cause skin cancers (melanoma and non-melanoma), cataracts, altered immunity as well as other deleterious effects on the environment, as well as to man-made substances like plastics

  3. General Background • Rule Making Procedures: • FDA interprets and implements its authority under the FD&C act and other statutes through regulations • Usual pathway for promulgation of a regulation is via publication of: Proposed Rule −Comment Period −Final Rule • Rulemaking integral to CFC/ODS essentiality determinations

  4. General Background • Development of FDA regulations and Montreal Protocol have proceeded in overlapping timeframes, so this talk will overlap the discussions

  5. History of the Montreal Protocol and 21 CFR 2.125 • 1974- Publication of work by Molina and Rowland tied stratospheric chlorine from degraded CFCs in the statosphere to ozone depletion1 • At that time, use of CFCs was widespread - refrigerators, A/C, foams, and in consumer and medical aerosol products 1 – Nature, 1974; vol 249:810-812

  6. History of the Montreal Protocol and 21 CFR 2.125 • 1978 – In response to growing evidence of CFCs harming the ozone layer, CFCs were generally banned in spray can/aerosols by US Govt (EPA) • FDA published 21 CFR 2.125 banning use of CFCs in FDA regulated products (with essential exemptions)

  7. History of the Montreal Protocol and 21 CFR 2.125 • 1987 - 27 nations (including U.S.) initiate a global ozone treaty in Montreal, known as the “Montreal Protocol (MP) on Substances that Deplete the Ozone Layer” • The original protocol now has 184 signatory Parties (countries) and is regarded as the model for successful, global environmental treaties

  8. History of the Montreal Protocol and 21 CFR 2.125 • Original phase-out of CFCs slated for 2000 (London - 1990) • Phase-out of CFCs is moved up to end of 1995 (Copenhagen - 1992) due to increasing evidence of growing ozone depletion, espeically over the Antartic (ozone “hole”) • While depletion is most prominent over southern hemisphere, the depletion is global • MP controls many ozone depleting substances (ODS): CFCs, Halons, HCFCs, methyl bromide, carbon tetrachloride,…

  9. History of the Montreal Protocol and 21 CFR 2.125 • As of January 1st, 1996, all use of CFCs banned in industrial countries; rest of the world in 2010 • MDIs for asthma and COPD currently exempted under essential use process • Nominations for essential uses reviewed annually (e.g., in 2004, UNEP reviews 2006 nominations)

  10. History of the Montreal Protocol and 21 CFR 2.125 Montreal Protocol has stipulated the following: • Decision IV/25 - All essential uses of CFCs based on products necessary for public health without adequate alternatives (technically & economically) - ‘macroscopic’ determination of essentiality (i.e., use of CFCs in MDIs for asthma and COPD)

  11. History of the Montreal Protocol and 21 CFR 2.125 Montreal Protocol has stipulated the following: • Decision XII/2 - Any product approved after Dec. 2000 must individually meet IV/25 - a product centered determination of essentiality that precludes new CFC generics

  12. History of the Montreal Protocol and 21 CFR 2.125 Montreal Protocol has stipulated the following: • Decision XV/5: • Essential use nominations are now use specific (e.g., XX tonnes for albuterol) • No quantity of essential use CFCs will be authorized for albuterol beginning with the MOP in 2005 if a “plan” has not been submitted by the OEWG the summer of 2005

  13. History of the Montreal Protocol and 21 CFR 2.125 • CAA amendments of 1990 codified MP into US law • Implementing EPA regulations refer to 21 CFR 2.125 for definition of medical essentiality • Again, 2.125 was finalized in 1978

  14. History of the Montreal Protocol and 21 CFR 2.125 • 1978 Federal Regulation (21 CFR 2.125) was promulgated stating that CFC containing regulated products were misbranded/adulterated unless deemed essential • “Essential” based on: • No technically feasible alternatives • Provides substantial (health, public, or environmental) benefit • Release of CFC small, or justified given benefit

  15. History of the Montreal Protocol and 21 CFR 2.125 • 1978 FDA rule had no mechanism to determine things no longer essential and to delist them (only mechanims to add new classes/drugs to the list) • Many important drugs not listed separately, but in broad classes • Adrenergic bronchodilators for human use…. • 1996, FDA publishes an Advanced Notice of Proposed Rulemaking (ANPR) proposing revisions to 2.125

  16. History of the Montreal Protocol and 21 CFR 2.125 • Close to 10,000 comments received, many sparked by lobbying efforts • NPR published in 1999 with fewer resulting substantive comments and little controversy • FR amending 2.125 published on July 24, 2002 • FR went into effect January 2003

  17. History of the Montreal Protocol and 21 CFR 2.125 In 2002 revisions: • Listed individual moieties as essential uses of ozone depleting substances (ODS) in 2.125 (e) rather than classes (e.g., albuterol is listed, rather than all adrenergic bronchodilators) • Added a higher hurdle for IND use of ODSs and to raise the bar for new listings of essential uses • Lists criteria for determining individual uses are no longer essential

  18. History of the Montreal Protocol and 21 CFR 2.125 Non-essentiality Criteria: • At least one non-ODS product with the same active moiety* , the same indication, route of administration, about the same level of convenience • At least 1 year of post-marketing data is available for the non-ODS product • Production capabilities and supplies are adequate • Patients who require the CFC product are adequately served * For products with only one marketed brand or strength

  19. History of the Montreal Protocol and 21 CFR 2.125 Non-essentiality Criteria (continued): • For Moieties with more than one available product/strength: • At least two non-ODS product with the same active moiety , the same indication, route of administration, about the same level of convenience • Other criteria the same • ALBUTEROL is a moiety with more than one product available (2 branded, 3 generics marketed)

  20. Trends in Global CFC essential uses: TEAP Report 2004

  21. CFC essential Use - then and now • Beta-agonists: isoethrane, isoprot., albuterol, epineph, metaprot., pirbuterol, bitoterol, salmeterol • ICS: fluticasone, flunisolide, TAA, BDP, Dexamethsone • Nasal Steroids • Cromones: Cromolyn, Nedocromil • Anticholinergics: Ipratropium, atropine • Albuterol/Ipratropium , Talc, Contraceptive Foams, Rectal CS foams, Ergotamine MDIs, Polymyxin, anesthetic drugs, NTG No longer essential; Delisting possible soon

  22. Conclusions • US Govt. moved proactively to address issue of ozone depletion and has had a key role in the Montreal Protocol • MP is a successful treaty, leading to important reductions in CFCs and other ODS • MP is increasingly moving towards control in specific essential uses, notably albuterol

More Related